Chronic kidney disease: Classification, mechanisms of progression and strategies for renoprotection;Enfermedad renal crónica: clasificación, mecanismos de progresión y estrategias de renoprotección

Revista Medica de Chile

Volumn 133, Issue 3, 2005, Pages 338-348

  Mezzano A , Sergio ^a   Aros E , Claudio ^a  

^a UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

Author keywords

Diabetic nephropathy; Glomerular filtration rate; Kidney diseases; Kidney failure; Proteinuria

Indexed keywords

ANIMAL; CHRONIC KIDNEY FAILURE; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY; NOMENCLATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PATHOPHYSIOLOGY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; TERMINOLOGY;

EID: 30844447238     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. U.S. RENAL DATA SYSTEM. USRDS 2003 Annual data Report: Atlas of end-stage renal disease in the Unites States. Bethesda, MD, National Institutes of Health, 2003, pp 1-560.
2. MITCH WE. Treating diabetic nephropathy - Are there only economic issues? N Engl J Med 2004; 351: 1934-6.
3. GO SA, CHERTOW GM, FAN D, MC CULLOCH CE, HSU CH-Y. Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. N Engl J Med 2004; 351: 1296-305.
4. ENCUESTA NACIONAL DE SALUD 2003. Disponible en http:/ /www.minsal.cl/ici/destacados/Folleto%20FINAL.pdf
5. EKNOYAN G, LAMEIRE N, BARSOUM R, ECKARDT K-U, LEVIN A, LEVIN N ET AL. The burden of kidney diseases: Improving global outcomes. Kidney Int 2004; 66: 1310-4.
6. NATIONAL KIDNEY FOUNDATION KD. Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Am J Kidney Dis 2002; 39 (suppl 1): S1-S266.
7. LEVEY AS. Nondiabetic kidney disease. N Engl J Med 2002; 347: 1505-11.
8. PLATT R. Structural and functional adaptation en renal failure. BMJ 1952; i; 1372-7.
9. BRENNER BM, MEYER TW, HOSTETTER TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodinamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsec renal disease. N Engl J Med 1982; 307: 652-9.
10. BERTANI T, CUTILLO F, ZOJA C, BROGGINI M, REMUZZI G. Tubulointerstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney Int 1986; 30: 488-96.
11. FOGO AB. Progression and potential regression of glomerulosclerosis. Kidney Int 2001; 50: 804-19.
12. MEZZANO SA, RUIZ-ORTEGA M, EGIDO J. Angiotensin II and renal fibrosis. Hypertension 2001; 38: 635-8.
13. RODRÍGUEZ-ITURBE B, HERRERA-ACOSTA J, JOHNSON RJ. Interstitial inflammation, sodium retention, and the pathogenesis of nephrotic edema: a unifying hypothesis. Kidney Int 2002; 62: 1379-84.
14. JOHNSON RJ, HERRERA-ACOSTA J, SCHREINER GF, RODRÍ-GUEZ-ITURBE B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002; 346: 913-23.
15. RUGGENENTI P, AROS C, REMUZZI G. Renin-angiotensin system, proteinuria, and tubulointerstitial damage. Contrib Nephrol 2001; 135: 187-99.
16. MEZZANO SA, RUIZ-ORTEGA M, EGIDO J. Angiotensin II and renal fibrosis. Hypertension 2001; 38: 635-8.
17. RUIZ-ORTEGA M, RUPEREZ M, LORENZO O, ESTEBAN V, BLANCO J, MEZZANO S ET AL. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int 2002; [Suppl] 82: S12-S22.
18. MEZZANO SA, DROGUETT MA, BURGOS ME, ARDILES LG, AROS CA, CAORSI I ET AL. Overexpression of chemokines, fibrogenic cytokines, and myofibroblasts in human membranous nephropathy. Kidney Int 2000; 57: 147-58.
19. MEZZANO SA, AROS CA, DROGUETT A, BURGOS ME, ARDILES LG, FLORES CA ET AL. Renal angiotensin II up-regulation and myofibroblast activation in human membranous nephropathy. Kidney Int 2003; [Suppl] 86: S39-S45.
20. MEZZANO S, DROGUETT A, BURGOS ME, ARDILES LG, FLORES CA, AROS CA ET AL. Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int 2003; [Suppl] 86: S64-S70.
21. MEZZANO S, AROS C, DROGUETT A, BURGOS ME, ARDILES L, FLORES C ET AL. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 2004; 19: 2505-12.
22. PARVING HH, ANDERSEN AR, SMIDT UM, SVENDSEN PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; 8335: 1175-9.
23. KES P, RATKOVIC-GUSIC I. The role of arterial hypertension in progression of renal failure. Kidney Int 1996; [Suppl] 55: S72-S74.
24. DE ZEEUW D. Albuminuria, not only a cardiovascular/ renal risk marker, but also a target for treatment? Kidney Int 2004; 66: S2-S6.
25. PETERSON JC, ADLER S, BURKART JM, GREENE T, HEBERT LA, HUNSIKER LG ET AL. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754-62.
26. THE DIABETES CONTROL AND COMPLICATIONS (DCCT) RESEARCH GROUP. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995; 47: 1703-20.
27. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
28. AROS C, REMUZZI G. The renin-angiotensin system in progression, remission and regression of chronic nephropathies. J Hypertens 2002; 20 [Suppl 3]: S45-S53.
29. LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.
30. MASCHIO G, ALBERTI D, JANIN G, LOCATELLI F, MANN JFE, MOTOLESE M ET AL. Effect of the angiotensinconverting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-45.
31. THE GISEN GROUP. Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-63.
32. JAFAR TH, SCHMID CH, LANDA M, GIATRAS I, TOTO R, REMUZZI G ET AL. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87.
33. AGODOA L, APPEL L, BAKRIS G, BECK G, BOURGOIGNIE J, BRIGGS JP ET AL. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. JAMA 2001; 285: 2719-28.
34. CAMPBELL R, SANGALLI F, PERTICUCCI E, AROS C, VISCARRA C, PERNA A ET AL. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003; 63: 1094-103.
35. NAKAO N, YOSHIMURA A, MORITA H, TAKADA M, KAYANO T, IDEURA T. Combination treatment of angiotensin-II receptor blocker and angiotensinconverting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 2003; 361: 117-24.
36. LEWIS EJ, HUNSICKER LG, CLARKE WR, BERL T, POHL MA, LEWIS JB ET AL. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
37. BRENNER BM, COOPER ME, DE ZEEUW D, KEANE WF, MITCH WE, PARVING HH ET AL. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
38. PARVING H-H, LEHNERT H, BROCHNER-MORTENSEN J, GOMIS R, ANDERSEN R, ARNER P ET AL. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
39. BARNETT AH, BAIN SC, BOUTER P, KARLBERG B, MADSBAD S, JERVELL J ET AL. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-61.
40. RUGGENENTI P, FASSI A, PARVANOVA-ILIEVA A, BRUNO S, PETROV-ILIEV I, BRUSEGAN V ET AL for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-51.
41. KLAHR S, LEVEY AS, BECK GJ, CAGGIULA AW, HUNSICKER L, KUSEK JW ET AL. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 1994: 330: 877-84.
42. SAMUELSSON O, MULES H, KNIGHT-GIBSON C, ATTMAN PO, KRON B, LARSSON R ET AL. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 1997; 12: 1908-15.
43. REMUZZI G. Cigarette smoking and renal function impairment. Am J Kidney Dis 1999; 33: 807-13.